RecruitingNot ApplicableNCT04873492

From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis

Sponsor

Nantes University Hospital

Enrollment

130 participants

Start Date

Jan 24, 2022

Study Type

INTERVENTIONAL

Conditions

Multiple Sclerosis

Summary

MS is a heterogeneous disease either in its response to treatment or clinical manifestation. Indeed, the natural history of MS is varying from a benign condition to a devastating and rapidly incapacitating disease. Clinical heterogeneity could also be cellular and / or molecular. The aim is to identify from OMIC analyses, at the early stage of the disease, differentially expressed molecules and / or cell subpopulations derived from CD8 + T lymphocytes and / or CD4 + T lymphocytes and / or B lymphocytes and monocytes from patients with aggressive versus non-aggressive, compared to a cohort of healthy controls

Eligibility

Min Age: 18 Years

Inclusion Criteria20

Common criteria for retrospective MS patients:
Patients aged 18 years or older
Clinical isolated syndrome (CIS) with or without dissemination in space
Patients affiliated to an appropriate health insurance
Criteria for Aggressive MS group
• Start of a 2nd line therapy within the two years following the CIS
Criteria for Non aggressive MS group
No conversion according to McDonald criteria from clinical isolated syndrome to multiple sclerosis within 2 years or
Conversion based to McDonald criteria treated or not with first line disease modifying therapy within 2 years.
Have a minimum of least 2 years of follow-up.
Healthy volunteers
Aged 18 years or older
No history of clinically isolated syndrome or MS
Pairing criteria :
Age +/- 5 years
Sex
Prospective MS Patients
Patients aged 18 years or older
Clinical isolated syndrome (CIS) with or without dissemination in space
Patients affiliated to an appropriate health insurance

Exclusion Criteria6

Ongoing participation to a another study
Refusal to genetic analyses
Immunosuppressive drug at the time of blood collection
Plasma exchange or corticosteroid treatment within the four weeks prior to blood sample
Adults under a legal protection regime (guardianship, trusteeship, judicial safeguard)
Pregnancy

Interventions

OTHERBiological sample collection

Venous blood sample will be collected from patients belonging to validation cohort and healthy volunteers at baseline resulting in 90 Ml EDTA tube and 10 ml serum tube. Approximately 100 ml will be collected. optional saliva and stool collection will be performed.